Objectives: Avoiding culprit agents is recommended for subjects who have had previous hypersensitivity reaction (HSR) to low-osmolar contrast media (LOCM). However, the guidelines for choosing optimal alternatives have not been determined. We investigated the outcomes of reexposure in patients with previous immediate HSRs to provide a safe option.

Materials And Methods: The outcomes of reexposure were assessed in a cohort with previous LOCM-associated HSR based on skin testing results and the presence of a common N-(2,3-dihydroxypropyl) carbamoyl side chain.

Results: Among 482 skin tests, 38.7% (31/80), 45.8% (99/216), and 64.0% (119/186) of mild, moderate, and severe index HSRs showed positivity to at least 1 LOCM, of which 62.8% showed positivity to at least 2 different LOCM. The overall recurrent HSRs were reduced from 43.8% upon reexposure to the culprit LOCM to 12.3% upon using nonculprit skin test negative LOCM (P = 0.004); those with severe index HSRs exhibited a significant reduction (11.3% vs 100%), but those with non-severe HSRs to LOCM did not. In subjects with severe index HSRs, the skin test cross-reactivity between LOCM was associated with sharing the common side chain (20.7% vs 11.5%, P = 0.003), and the recurrence rate of HSRs was effectively reduced by avoiding the common side chain (24.0% vs 7.8%, P = 0.039). However, these differences were not observed in those with non-severe index HSRs.

Conclusions: In patients who experienced a severe index HSR to LOCM, skin test negative LOCM without a common side chain could be suggested as an option for safe reexposure.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLI.0000000000000765DOI Listing

Publication Analysis

Top Keywords

severe hsrs
12
skin test
12
common side
12
side chain
12
locm
9
outcomes reexposure
8
positivity locm
8
test negative
8
negative locm
8
hsrs
7

Similar Publications

Comparative Safety Profiles and Usage Patterns of Iodinated Contrast Media in Medical Imaging.

Diagnostics (Basel)

November 2024

Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 07345, Republic of Korea.

Objectives: This study aimed to analyze the usage patterns and hypersensitivity reaction (HSR) profiles of six nonionic iodinated contrast media (ICMs) used in computed tomography (CT) to enhance patient safety and inform evidence-based contrast agent selection.

Methods: We retrospectively reviewed 248,209 CT scans obtained between January 2020 and December 2022. Six ICMs (iomeprol, iohexol, ioversol, iopromide, iodixanol, and iobitridol) were compared on the basis of their usage rates, HSR incidence, and severity.

View Article and Find Full Text PDF

Background: Following the increased use of biological agents, a subset of patients experiences hypersensitivity reaction (HSR). We reported our experience with rapid drug desensitization (RDD) to nine biologics (rituximab, infliximab, cetuximab, trastuzumab, pertuzumab, nivolumab, brentuximab, tocilizumab and filgrastim) and identified risk factors for breakthrough reactions (BTRs).

Method: This was a retrospective review (2013-2022) of patients with immediate HSRs to biological agents.

View Article and Find Full Text PDF
Article Synopsis
  • In Taiwan, nonionic iodinated contrast media (ICMs) are widely used but can sometimes lead to severe adverse reactions, making it challenging to investigate the genetic factors behind these side effects.
  • A genome-wide association study (GWAS) was conducted using data from two cohorts: one assessing immediate reactions through adverse drug reports, and the other focusing on delayed reactions from self-reports, ultimately identifying multiple risk loci and causal variants.
  • The findings suggest that different genes are involved in immediate and non-immediate hypersensitivity reactions to ICMs, providing insight into their genetic basis within the Taiwanese population.
View Article and Find Full Text PDF
Article Synopsis
  • * Out of 197 pediatric IBD patients, 61 were treated with BDs, and 6 patients experienced I-HSRs, primarily mild to moderate and mostly associated with infliximab.
  • * The presence of comorbid allergic diseases significantly increases the risk of developing I-HSRs in these patients, suggesting careful monitoring during BD treatment.
View Article and Find Full Text PDF

Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes.

Allergy

August 2024

Allergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain.

Background: Delabelling pathways offer confirmatory diagnosis and can prevent unnecessary second-line therapies or drug desensitization procedures after chemotherapeutic hypersensitivity reactions (CHT-HSRs). However, these pathways rely on risky in vivo tests. Data on whether in vitro tests could be helpful are scarce.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!